Article | July 2, 2020

Impurity Identification In Small-Molecule APIs

Source: Albemarle
small molecule, nce

Timely identification of impurities is critical for maintaining clinical and marketing timelines, and it requires a unique combination of process chemistry knowledge and considerable analytical capabilities. At Albemarle Fine Chemistry, we keep customers on track by combining decades of pharma research and development experience with teams who closely collaborate on all elements of process development, from the kilo lab to commercial production.

These teams are formed early in process development and then maintained through all phases of commercial development. This ensures that when an impurity arises, the pieces are already in place for prompt identification, and the team just needs to execute.

Impurities of principal concern are often first discovered through final product purity analysis, which for most small molecule drug substances utilizes high-performance liquid chromatography (HPLC) with UV detection. However, tracking and identification of impurities observed in in-process control testing, along with purity analysis of raw materials, is the strategy most likely to lead to successful management of a drug’s total impurity profile.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Outsourced Pharma? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: